Hydroxypropyl-beta-cyclodextrin
(Synonyms: 2-羟丙基-β-环糊精) 目录号 : GC19722
Hydroxypropyl-beta-cyclodextrin一种由beta-Cyclodextrin与环氧丙烷反应生成的醚化衍生物,可通过疏水空腔包合难溶性药物分子,形成水溶性复合物,显著提高药物的溶解度和生物利用度,并可作为药物赋形剂用于口服、注射和黏膜给药系统。
Cas No.:94035-02-6
Sample solution is provided at 25 µL, 10mM.
Hydroxypropyl-beta-cyclodextrin is an ether derivative generated by the reaction of beta-Cyclodextrin with epichlorohydrin[1]. Hydroxypropyl-beta-cyclodextrin can form water-soluble complexes by encapsulating poorly soluble drug molecules in hydrophobic cavity, significantly enhancing the solubility and bioavailability of the drugs. Hydroxypropyl-beta-cyclodextrin can also be used as a pharmaceutical excipient in oral, injectable, and mucosal drug delivery systems[2]. Hydroxypropyl-beta-cyclodextrin can bind and dissolve cholesterol crystals within cells, promote cholesterol efflux and metabolism, and enhance lysosomal function and autophagic clearance by activating transcription factor EB[3]. Hydroxypropyl-beta-cyclodextrin can disrupt cholesterol homeostasis, inducing G2/M cell cycle arrest and apoptosis in leukemia cells, and systemic administration has been shown to be safe[4].
In vitro, after pre-treatment of bone marrow-derived macrophages (BMDMs) with Hydroxypropyl-beta-cyclodextrin (1.95mM) for 4 hours, followed by stimulation with lipopolysaccharide (LPS; 100ng/ml) for 4 hours, Hydroxypropyl-beta-cyclodextrin significantly increased the protein secretion of the pro-inflammatory cytokine TNF-α, upregulated the expression of pro-inflammatory genes, and downregulated the expression of anti-inflammatory genes[5]. Hydroxypropyl-beta-cyclodextrin (2.5–20mM) pre-treatment of Vero E6 cells and Calu-3 lung epithelial cells for 1 hour, followed by infection with SARS-CoV-2 (MOI = 0.1–0.5) for 24–72 hours, significantly inhibited viral replication and reduced virus-induced inflammation[6].
In vivo, Hydroxypropyl-beta-cyclodextrin (4000mg/kg; intraperitoneal injection twice a week) was used to treat Tg19959 Alzheimer's disease model mice for 4 months. Hydroxypropyl-beta-cyclodextrin significantly improved the learning and memory functions of the mice, reduced amyloid-beta (Aβ) plaque deposition, and attenuated tau pathology in the brain[7]. Hydroxypropyl-beta-cyclodextrin (10% w/v) was used as a drug carrier and administered intravenously three times a week (at a dose of 2.5–20mg/kg) to NOD/SCID mice that had been inoculated with SU-DHL-6 tumor cells. Hydroxypropyl-beta-cyclodextrin significantly increased the water solubility of Purinostat Mesylate (PM), enhanced its anti-tumor efficacy, and improved its pharmacokinetic properties[8].
References:
[1] Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005 Oct;43(10):1451-9.
[2] Li J, Li Y, Su W, et al. In vivo anti-obesity efficacy of fucoxanthin/HP-β-CD nanofibers in high-fat diet induced obese mice. Food Chem. 2023 Dec 15;429:136790.
[3] Castiblanco D, Rudd-Schmidt JA, Noori T, et al. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1. Blood. 2022 Mar 24;139(12):1833-1849.
[4] Yokoo M, Kubota Y, Motoyama K, et al. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 2015 Nov 4;10(11):e0141946.
[5] Houben T, Yadati T, de Kruijf R, et al. Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment. Front Immunol. 2021 Aug 20;12:716357.
[6] Bezerra BB, Silva GPDD, Coelho SVA, et al. Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines. Antiviral Res. 2022 Sep;205:105373.
[7] Yao J, Ho D, Calingasan NY, et al. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J Exp Med. 2012 Dec 17;209(13):2501-13.
[8] Zhu Z, Wen J, Xu Y, et al. Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model. Ann Med. 2022 Dec;54(1):743-753.
Hydroxypropyl-beta-cyclodextrin一种由beta-Cyclodextrin与环氧丙烷反应生成的醚化衍生物[1],可通过疏水空腔包合难溶性药物分子,形成水溶性复合物,显著提高药物的溶解度和生物利用度,并可作为药物赋形剂用于口服、注射和黏膜给药系统[2]。Hydroxypropyl-beta-cyclodextrin够结合并溶解细胞内的胆固醇晶体,促进胆固醇外流和代谢,并通过激活转录因子EB增强溶酶体功能和自噬清除能力[3]。Hydroxypropyl-beta-cyclodextrin通过扰乱胆固醇稳态,诱导白血病细胞G2/M期周期阻滞和凋亡,且系统性给药具有安全性[4]。
在体外,Hydroxypropyl-beta-cyclodextrin(1.95mM)预处理骨髓来源的巨噬细胞(BMDMs)4小时后,随后以脂多糖(LPS,100ng/ml)刺激4h,Hydroxypropyl-beta-cyclodextrin显著增加促炎因子TNF-α的蛋白分泌,同时升高促炎基因的表达水平,降低抗炎基因的表达水平[5]。Hydroxypropyl-beta-cyclodextrin(2.5–20mM)预处理Vero E6细胞和Calu-3肺上皮细胞1小时,随后以SARS-CoV-2(MOI=0.1–0.5)感染24–72小时,Hydroxypropyl-beta-cyclodextrin显著抑制病毒复制,同时降低病毒诱导的炎症反[6]。
在体内,Hydroxypropyl-beta-cyclodextrin(4000mg/kg;每周两次腹腔注射),用于处理Tg19959阿尔茨海默病模型小鼠,持续4个月,显著改善了小鼠的学习和记忆功能,同时减少了脑内Aβ斑块沉积和tau病理[7]。Hydroxypropyl-beta-cyclodextrin(10% w/v)作为药物载体,通过每周三次静脉注射(剂量为2.5–20mg/kg),用于处理已接种SU-DHL-6肿瘤细胞的NOD/SCID小鼠。Hydroxypropyl-beta-cyclodextrin显著提高了Purinostat Mesylate(PM)的水溶性,增强了其抗肿瘤疗效,并改善了药代动力学特性[8]。
| Cell experiment [1]: | |
Cell lines | Vero E6 cells (African green monkey kidney epithelial cell line) |
Preparation Method | Vero E6 cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were pretreated with Hydroxypropyl-beta-cyclodextrin at concentrations of 5-20mM for 1 hour, followed by infection with SARS-CoV-2 (MOI=0.1) for 1 hour. The virus inoculum was then replaced with fresh medium, and cells were cultured for up to 72 hours. |
Reaction Conditions | 5-20mM; 1-hours pretreatment |
Applications | Hydroxypropyl-beta-cyclodextrin pretreatment significantly inhibited SARS-CoV-2 replication, reducing intracellular viral genomic RNA (gRNA) and subgenomic RNA (sgRNA) levels. Hydroxypropyl-beta-cyclodextrin also markedly decreased the production of infectious virus particles, leading to a reduction in viral titer by over 90%. |
| Animal experiment [2]: | |
Animal models | Tg19959 transgenic mice (overexpressing human APP with Swedish and Indiana familial AD mutations) |
Preparation Method | Mice were subcutaneously administered Hydroxypropyl-beta-cyclodextrin (4000mg/kg, 20% w/v solution in isotonic saline) twice weekly, starting at postnatal day 7 (P7) and continuing for 4 months. Control mice received saline injections on the same schedule. |
Dosage form | 4000mg/kg; s.c. |
Applications | Hydroxypropyl-beta-cyclodextrin administration significantly improved spatial learning and memory deficits in the Morris water maze test. Hydroxypropyl-beta-cyclodextrin also markedly diminished Aβ plaque deposition in both the cerebral cortex and hippocampus, and reduced the area occupied by phosphorylated tau (AT8)-immunoreactive dystrophic neurites. |
References: | |
| Cas No. | 94035-02-6 | SDF | |
| 别名 | 2-羟丙基-β-环糊精 | ||
| 化学名 | Cyclodextrin;Hydroxypropyl-SS-Cyclodextrin | ||
| 分子式 | C42.(H)70-n.O35.(C3H7)n | 分子量 | |
| 溶解度 | 储存条件 | Store at 2-8℃ | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet















